Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States-Reference-Cited by-同舟云学术

Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States

Published:2014-10-24 Issue:11 Volume:66 Page:1604-1611
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Curtis Jeffrey R.¹,Zhang Jie¹,Xie Fenglong¹,Beukelman Tim¹,Chen Lang¹,Fernandes Joaquim²,Ginsberg Seth³,Spettell Claire²,Yun Huifeng¹,Saag Kenneth G.¹,Schiff Michael⁴

Affiliation:

1. University of Alabama; Birmingham

2. Aetna Informatics; Blue Bell Pennsylvania

3. CreakyJoints; New York New York

4. University of Colorado; Denver

Funder

Agency for Healthcare Research and Quality

Antares Pharma

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.22383/fullpdf

Reference26 articles.

1. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

2. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis;Hamilton;Br J Rheumatol,1997

3. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis;Hoekstra;J Rheumatol,2004

4. Is parenteral methotrexate worth trying?;Osman;Ann Rheum Dis,2001

5. Parenteral methotrexate should be given before biological therapy;Bingham;Rheumatology (Oxford),2003

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Barriers and Enablers in the Use of Parenteral Methotrexate in Rheumatoid Arthritis Patients: A Scoping Review;Arthritis Care & Research;2023-06-12

2. POS0989-HPR REAL-WORLD INDUCTION DMARD THERAPY IN RHEUMATOID ARTHRITIS; INSIGHTS IN THE DUTCH SANTEON BENCHMARK FRAMEWORK TO IMPROVE PATIENT CARE;Health Professionals in Rheumatology Abstracts;2023-05-30

3. Long-term persistence of oral methotrexate and associated factors in rheumatoid arthritis: a retrospective cohort study;Rheumatology International;2023-03-18

4. Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis;Expert Review of Molecular Diagnostics;2022-10-03

5. Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis;Expert Opinion on Biological Therapy;2022-04-23